bannertutte

Nicox Research Institute

 zoner nicox

Nicox is an emerging international company in the ophthalmic market building a diversified portfolio of innovative therapies and diagnostic tools addressing the needs of eyecare practitioners and patients around the world.

SFONDO-NICOX2

Nicox has developed a leading position in the therapeutic application of novel NO-donating compounds based on a strong proprietary research platform.

The Company’s Research subsidiary is focusing its efforts in the ophthalmic field where nitric oxide has been shown to play an important role and is working in close collaboration with Universities and Research Institutions, on several compounds for ocular disorders.

Nicox is also partnering with pharmaceutical companies, such as Bausch + Lomb and Merck (known as MSD outside the United States and Canada), to further advance programs and develop promising NO-donating new molecular entities.

Nicox is headquartered in Sophia Antipolis (France) and has North-American Operations based in Fort Worth (Texas, United States). Its Research Center is based in Bresso (Italy).

Nicox is listed on Euronext Paris (Compartment B: Small Caps) with the trading symbol COX.

Nicox Farma
Nicox is a new international ophthalmic company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

We have already successfully completed 4 acquisitions in the ophthalmic area and we continue to actively seek and evaluate commercial and late-stage ophthalmic products as well as potential acquisitions of local ophthalmic companies in Europe’s largest markets.
Our global growth strategy is focused on outstanding international collaborations and on our proprietary nitric oxide-donating research platform.

A growing commercial portfolio

Our commercial portfolio currently includes the Xailin range of ocular products and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. We also market a number of other ophthalmic products through our subsidiaries in Italy and in France, following the acquisitions of EuPharmed in December 2013 and of Doliage in September 2014, respectively.

We have a direct commercial presence in the five largest European markets (Germany, France, the United Kingdom, Italy and Spain), as well as partnerships with local distributors in a number of key international markets.